Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $22.72M
• Dividend Yield: N/A
• Average Volume (3M): 88.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.63
• Revenue Growth: -50.49%
• EPS Growth: 39.93%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.53
• Shares Outstanding: 12,279,181
• 10 Day Avg. Volume: 45,410
• 30 Day Avg. Volume: 88,723
• PEG Ratio: 0.01
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 1.90
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: -1.29
• 1Y Price Target: $6.00
• Price Target Upside: 224.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -3.61
• Revenue Forecast (FY): $16.04M

• Rating: 49 Neutral
• Price Target: $2.00 ▲(8.11% Upside)

Overall score is held back primarily by weak financial performance: contracting revenue, large ongoing losses, heavy cash burn, and negative equity. Offsetting factors include improving cost control and constructive FDA/regulatory and balance-sheet restructuring progress discussed on the earnings call, plus moderately positive technical momentum. Valuation remains difficult to support due to negative earnings and no dividend yield provided.

Positive Factors

Regulatory progress (FDA milestones)

Clearing key FDA substantive review steps with no observations materially increases probability of U.S. market access for the Allurion Smart Capsule. Regulatory readiness is a durable value driver that can enable scalable commercial adoption, reimbursement discussions, and strategic partnerships over 2–6 months+.

Product-level gross margins

Sustained product-level gross margins near 60% indicate healthy unit economics for the balloon program and services. With fixed-cost leverage and lower operating scale, strong gross margins provide a structural cushion to improve profitability as revenue stabilizes or grows, supporting long-term margin recovery.

Operating-cost discipline

A 29% reduction in operating expenses and improved operating loss reflect structural cost realignment. Sustained expense discipline reduces ongoing cash burn, extends runway, and makes the business more resilient while management executes commercialization and regulatory milestones over the medium term.

Negative Factors

Multi-year revenue decline

A multi-year revenue downtrend signals weakening market traction or product adoption. Structural recovery will require successful commercialization, new product approvals, or durable reimbursement gains; absent that, fixed costs and R&D pressures can hinder sustainable profitability for several quarters.

Persistent negative cash flow

Large, ongoing negative operating and free cash flow highlight structural cash burn that necessitates recurring financing or rapid revenue inflection. Persistent negative cash generation constrains reinvestment, increases dilution or refinancing risk, and limits strategic optionality over the medium term.

Highly stressed balance sheet

Material negative equity and sizable debt versus a small asset base reduce balance-sheet flexibility and elevate refinancing risk. Structural solvency concerns can limit access to favorable financing, pressure governance/capital actions, and increase the likelihood of dilutive transactions while management executes turnaround plans.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

How the Company Makes Money

Allurion Technologies generates revenue through the sale of its medical devices, particularly the Allurion Balloon and associated services. The company typically sells its products directly to healthcare providers, hospitals, and clinics, which then offer these solutions to patients seeking weight loss options. Additionally, Allurion has developed partnerships with healthcare institutions and professionals to enhance the distribution of its products and services, creating a network that expands its market reach. The company may also generate income through subscription services for ongoing support and coaching, contributing to a recurring revenue model. Furthermore, Allurion's collaborations with insurance companies can facilitate reimbursement for its products, enhancing access to patients and driving sales.

Allurion Technologies Financial Statement Overview

Summary

Allurion Technologies faces significant financial challenges, including declining revenue, persistent losses, high leverage, and negative cash flows. Strategic changes are necessary to stabilize and improve financial health in a highly competitive medical devices industry.

Income Statement

Allurion Technologies has experienced significant revenue fluctuations, with a notable decline from 2022 to 2023. The company faces negative profit margins, including a negative gross profit margin in 2024, and sustained losses in net income, EBIT, and EBITDA, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and high leverage as indicated by a high debt-to-equity ratio. The equity ratio is negative, reflecting a risk of insolvency, compounded by the decline in assets and insufficient equity to cover liabilities.

Cash Flow

Cash flow analysis shows persistently negative operating and free cash flows, signaling liquidity issues. The company has relied heavily on financing activities to fund operations, which is unsustainable in the long term without improved financial performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.21M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	10.49M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-33.37M	-22.17M	-69.03M	-32.28M	-8.01M	201.13K
Net Income	-43.29M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	18.14M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	6.14M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	33.39M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	101.07M	110.79M	142.20M	83.68M	73.64M	310.13K
Stockholders Equity	-82.93M	-77.98M	-70.49M	-32.31M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-36.90M	-42.91M	-65.59M	-48.53M	-15.24M	-40.00
Operating Cash Flow	-36.90M	-42.30M	-63.98M	-46.98M	-14.33M	―
Investing Cash Flow	0.00	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	14.32M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Positive. The current price of 1.85 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.54, and below the 200-day MA of 2.22, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.91 is Neutral, neither overbought nor oversold. The STOCH value of 80.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALUR	49 Neutral	$22.72M	-0.25	―	―	-50.49%	39.93%
XAIR	47 Neutral	$13.62M	-0.23	-179.63%	―	147.74%	73.23%
IRIX	46 Neutral	$24.24M	-4.66	-139.29%	―	4.58%	55.26%
CODX	44 Neutral	$5.93M	-0.10	-62.12%	―	-87.84%	29.16%
NVNO	43 Neutral	$6.91M	-0.30	-57.19%	―	―	18.94%
SINT	40 Underperform	$14.41M	-0.54	-204.04%	―	-60.89%	94.49%

Allurion Technologies Corporate Events

Allurion Shareholders Approve Governance Changes and Capital Actions

At its annual meeting on December 18, 2025, Allurion Technologies, Inc. re-elected directors Omar Ishrak, Douglas Hudson and R. Jason Richey to serve until the 2028 annual meeting and ratified Deloitte & Touche LLP as its independent auditor for the 2025 fiscal year. Shareholders also approved an amended and restated 2023 Stock Option and Incentive Plan that increases the share pool, extends the plan term, revises the fully diluted share definition and lowers non-employee director compensation limits, as well as the repricing of certain existing stock options. In addition, investors authorized the issuance of common shares upon conversion of Series B preferred stock and the exercise of private placement warrants to ensure compliance with New York Stock Exchange listing rules, and backed a share consolidation authorization allowing the board to implement a reverse stock split in a range of 1-for-1.5 to 1-for-20, steps that collectively enhance the company’s capital structure flexibility and support its continued listing and governance framework.

The most recent analyst rating on (ALUR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies Secures $5M in New Funding

On November 11, 2025, Allurion Technologies entered into a securities purchase agreement to sell shares and warrants for approximately $5 million, aiming to strengthen its balance sheet. Concurrently, the company agreed to exchange outstanding debt for convertible preferred equity with RTW Investments, which will allow RTW to convert debt into Series B Preferred Stock, enhancing Allurion’s financial position. These strategic financial maneuvers are part of Allurion’s broader efforts to secure FDA approval for its products and position itself for long-term success in the weight-loss industry.

The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.